NCT03634982 - Dose Escalation of RMC-4630 Monotherapy in Relapsed/Refractory Solid Tumors | Biotech Hunter

Enrollment

133

Participants

Timeline

Start Date

September 28, 2018

Primary Completion Date

March 31, 2023

Study Completion Date

May 31, 2023

Conditions

Solid Tumors

Interventions

DRUG

RMC-4630

RMC-4630 for oral administration

Trial Locations (12)

Moffit Cancer Center, Tampa

Sarah Cannon Research Institute - Florida Cancer Specialists, Sarasota

Sarah Cannon Research Institute - Tennessee Oncology, PLLC, Nashville

University of Oklahoma - Stephenson Cancer Center, Oklahoma City

University of Texas at Austin - Dell Medical School, Austin

University of Colorado Cancer Center, Aurora

Honor Health Research Institute, Scottsdale

City of Hope, Duarte

UC Irvine - Chao Family Comprehensive Cancer Center, Orange

UC San Francisco - Helen Diller Family Comprehensive Cancer Center, San Francisco

UC Davis Comprehensive Cancer Center, Sacramento

Dana-Farber Cancer Institute, Boston